FOSTER CITY, Calif. - Gilead Sciences Inc. announced Thursday it has donated more than 2,000 vials of remdesivir to Uganda to support response efforts to an outbreak of Ebola Bundibugyo virus disease.The $156 billion biotechnology company, currently trading below its InvestingPro Fair Value estimate, has positioned itself as a prominent player in responding to global health emergencies.
The company stated it is preparing additional supply and working with partners including the Democratic Republic of the Congo and the World Health Organization to provide both remdesivir and obeldesivir, an oral investigational antiviral agent, according to a press release statement.
Remdesivir is being provided under compassionate use and Monitored Emergency Use of Unregistered and Investigational Interventions frameworks for treating the disease. The drug has demonstrated preclinical activity against multiple filoviruses but has not been approved for treatment of filovirus disease in any country.
The safety and efficacy of remdesivir for the Bundibugyo strain have not been established. Gilead said ongoing studies are working to generate this evidence.
Gilead is also preparing to support several planned clinical trials as part of the broader regional response to Ebola Bundibugyo virus disease.
Remdesivir, a nucleotide analog prodrug, has shown broad-spectrum antiviral activity in laboratory and animal studies against viral pathogens including Marburg, Ebola, SARS, MERS and SARS-CoV-2. The drug has been approved as a COVID-19 treatment in approximately 50 countries and has been made available to more than 14.5 million patients worldwide.Gilead’s financial strength supports its humanitarian efforts, with the company generating nearly $30 billion in annual revenue and maintaining a dividend that has increased for 11 consecutive years. For deeper insights into Gilead’s financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, one of 1,400+ US equities covered.
Over the past decade, Gilead has provided remdesivir donations for multiple filovirus outbreaks in Sub-Saharan Africa through emergency and compassionate use programs, as well as for investigational use in clinical trials.
The emergency use donation is based on preclinical data for Ebola virus combined with clinical safety data from remdesivir’s use in treating COVID-19, the company stated.
In other recent news, Gilead Sciences and Merck announced that their investigational once-weekly oral HIV treatment met the primary efficacy endpoint in two Phase 3 trials, ISLEND-1 and ISLEND-2. These trials evaluated the combination of islatravir and lenacapavir in virologically suppressed patients. However, the companies also decided to discontinue the Phase 3 KEYNOTE-D46/EVOKE-03 study for lung cancer treatment after a recommendation from an external Data Monitoring Committee. This decision was based on the analysis of progression-free survival and interim overall survival data. In corporate developments, Gilead and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. The acquisition involved an upfront payment of $1,675 million, with potential additional milestone payments. On the financial front, Cantor Fitzgerald reiterated an Overweight rating for Gilead Sciences, maintaining a $155.00 price target following the HIV trial data. Meanwhile, RBC Capital reiterated a Sector Perform rating, with a $122.00 price target, commenting on Gilead’s position in the in vivo CAR-T therapy space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for GILD plus thousands of other stocks and find your next hidden gem with massive upside.